Background/Target. Growth factor treatment could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of colony stimulating factor (CSF) and recombinant human (rHu) granulocyte stimulating factor (GSF) on experimental colitis in rats. methods . Experimental colitis was induced in 62 male Wistar rats divided into 9 groups using 2,4,6-trinitrobenzenesulfonic acid (TNBS). Group 1: Ten rats with colitis without treatment (control group). Euthanasia after 15 days. Group 2: Ten animals with colitis without treatment (control group). Euthanasia after 30 days. Group 3: Six animals with colitis. Immediate treatment with CSF. Euthanasia after 19 days. Group 4: Six animals with colitis. Treatment began 7 days after colitis induction. The animals were kept for 19 days. Group 5: Six animals with colitis. Treatment began 2 weeks after induction of colitis.
Group 6: Six animals with colitis, same as in group 3. Treatment with GSF. Group 7: Six animals with colitis, the same as in group 4. Treatment with GSF. Group 8. Six animals with colitis same as in Group 5. Treatment with GSF. Group 9: Six animals with colitis. Immediate treatment with prednisolone. Euthanasia after 15 days. Results . CSF and GSF administration significantly improved histological score (□ ) and reduced malondialdehyde content ( □ ) in all animals compared to control groups. CSF was superior to GSF and prednisolone. Conclusion .Administration of both CSF and GSF could significantly improve histological score and oxidative stress in experimental colitis in rats.
introduction
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease of the gastrointestinal tract with two main entities, Crohn’s disease (CD) and ulcerative colitis (UC). The primary therapeutic goals are to improve quality of life by inducing and maintaining remission, predicting, preventing, and treating complications, restoring nutritional deficiencies, and altering the natural history of the disease. A dysfunctional innate immune system could be instrumental in the pathogenesis of CD. Therefore, treatments aimed at overcoming congenital immunodeficiencies could represent valuable therapeutic alternatives.
Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor [GM-CSF (rHu GM-CSF)] [Molgramostim (Mielogen)] is a human protein produced by a strain of Escherichia coli containing a plasmid encoding the human GM-CSF gene encoded. Cells expressing receptors for GM-CSF include neutrophils, monocytes, macrophages and antigen presenting cells. These receptors are also produced by specialized intestinal epithelial cells, including Paneth cells and CD4 T lymphocyte cells. Molgramostim stimulates the formation of macrophage colonies, which are essential for the process of hematopoiesis and the function of mature myeloid cells.In addition, molgramostim increases white blood cell count and functions, increases antimicrobial phagocytosis, and promotes oxidative metabolism, functions associated with the host’s innate immunological defense mechanisms.
Lenograstim is the glycosylated recombinant form of human granulocyte colony-stimulating factor with effects similar to molgramostim . Lenograstim is a valuable adjunct capable of minimizing the hematological toxicity of myelosuppressive chemotherapy in patients with malignancies .
Of the currently used animal models, 2,4,6-trinitrobenzenesulfonic acid ( TNBS )-induced colitis resembles human IBD in its various histological features, including infiltration of the colonic mucosa by neutrophils and macrophages and increased production of inflammatory mediators. The immune-stimulating functions of growth factors could potentially be beneficial in patients with IBD.
Finally, malondialdehyde (MDA) is one of the end products of lipid peroxidation in cells. An increase in free radicals during an inflammatory process such as colitis causes an overproduction of MDA. For this reason, MDA levels are often used as a marker for oxidative stress.
The aim of this study was to examine the influence of the two growth factors; Granulocyte colony-stimulating factor (G-CSF, Lenograstim) and recombinant human granulocyte-macrophage colony-stimulating factor (rHu GM-CSF, Molgramostim, Mielogen) ] as potential therapeutics in experimental colitis in rats.
MATERIALS AND METHODS
experimental animals
Sixty-two male Wistar rats weighing more than 250 g were used. The animals were housed in the laboratory for at least 10 days prior to the experiment according to international regulations. The experimental procedures described below have been approved by the Animal Care Committee under European Union Law and Greek Law 160, A-64, May 1991 and are designed to minimize pain and discomfort to the animals. All animals were euthanized by barbiturate overdose (150 mg/kg pentobarbital sodium). Choosing different time points at which euthanasia was performed allowed us to examine clinical worsening or remission of colitis over different time intervals.
Induction of experimental colitis
Distal colitis was induced by intracolonial installation of 25 mg TNBS dissolved in 0.25 ml 50% ethanol. The solution was injected into the colon 8 cm proximal to the anus using a PE-50 needle. To ensure that the TNBS-ethanol solution was not immediately excreted from the rat, the cannula was left in place for 15 s prior to its removal.
groups
The animals were divided into 9 groups. The first two groups consisted of ten rats each (control groups, total of 20 animals). All other groups consisted of 6 rats each (42 animals in total). The number of animals used per group was based on a similar estimate to those used in other relevant studies in the literature. These numbers were the highest possible for the available budget to allow safe conclusions. In other words, we recruited the highest possible number of mice for the given budget; We also internally allocated a specific number of mice per group and compared this to other studies with a similar focus to ensure that reasonable study power was achieved within cost constraints.
Prednisolone was chosen as a positive control group.
The nine groups were as follows : Group 1: Ten rats with TNBS colitis without treatment (control group 1). Euthanasia was performed after 15 days. Group 2: Ten animals with TNBS colitis, again without treatment (control group 2). Euthanasia was performed after 30 days. Group 3: Six animals with TNBS colitis. Immediate treatment with liquor. Euthanasia was performed after 19 days. Group 4: Six animals with TNBS colitis. CSF treatment began 7 days after colitis induction.
Euthanasia was performed after 19 days. Group 5: Six animals with TNBS colitis. CSF treatment began 14 days after colitis induction. Euthanasia was performed after 19 days. Group 6: Six animals with TNBS colitis, immediate treatment with GSF. Euthanasia was performed after 19 days. Group 7: Six animals with TNBS colitis, treatment with GSF started 7 days after colitis induction. Euthanasia was performed after 19 days. Group 8. Six animals with TNBS colitis, treatment with GSF started 14 days after colitis induction. Euthanasia was performed after 19 days . Group 9: Six animals with TNBS colitis. Immediate treatment with prednisolone and euthanasia after 15 days.
pathology
The resected tissue samples were fixed in 10% buffered formaldehyde and each sample was completely embedded in 3-4 paraffin blocks depending on the size. Histological sections from each block were cut at 4 μm thickness and stained with hematoxylin-eosin [ 8 ]. First, the sections were blindly examined separately by two pathologists (CB and AN) and a finally agreed histological diagnosis was made. Results were evaluated using the Geboes [ 9 ] Histological score based on the following features: normal histology, acute ulcers/erosions/chronic ulcers, neutrophilic activity, crypt distortion, and chronic inflammation of the lamina propria. The above features were diagnostic of induced colitis. Based on this score, the colonic mucosa was characterized as normal (grade 0), colitis in remission (grades 1 and 2), and active colitis (grades 3-5). The histological features of healing ulcers with complete or incomplete re-epithelialization, crypt loss and lamina propria/submucosa fibrosis or crypt regeneration were evaluated as signs of remission.
Tissue Malondialdehyde Estimate
The malondialdehyde(MDA) measurement was based on the reaction of a chromogenic reagent, N -methyl-2-phenylindole (MPI), with MDA at 45°C. Reagents used included Reagent MPI , 10.3 mmol/L N -Methyl-2-phenylindole in acetonitrile, MDA standard , 10 mmol/L 1,1,3,3-Tetramethoxypropane in 20 mmol/L Tris-HCl, 500 mmol/L butylated hydroxytoluene, in acetonitrile, 20 mmol/L Tris buffer pH 7.4, 0.9% NaCl, 37% (12 mol/L) HCl, methanol, HPLC grade, acetonitrile and HPLC grade. Before the procedure, three volumes of MPI reagent were diluted with one volume of 100% methanol. Tissue samples were rinsed with ice-cold isotonic saline prior to homogenization, which was performed using Tris buffer 20 mmol/L pH 7.4 and an ULTRA-TURRAX (IKA-Labortechnik) blender. One milliliter of buffer was used for 0.1 g of tissue.
Molgramostim (rHuGM-CSF)
rHuGM-CSF
Amyotop
300µg/vial
249 EUR
PRE-GMP rHu GM-CSF, Molgramostim-Leukoma
04-RHUGM-CSF-7A10
Gentaur Genprice
300 µg
385 EUR
Filgrastim (rHuG-CSF)
rHuG-CSF
Amyotop
300µg/vial
225 EUR
Mouse GM-CSF ELISA Kit, 96 tests, Quantitative
MGM-CSF-100
Alpha Diagnostics
1 kit
482 EUR
Human GM-CSF ELISA Kit, 96 tests, Quantitative
HGM-CSF-100
Alpha Diagnostics
1 kit
482 EUR
CSF/ Rat CSF ELISA Kit
ELA-E1111r
Lifescience Market
96 Tests
886 EUR
G-CSF
E21-002
EnoGene
10ug
343 EUR
GM-CSF
E21-003
EnoGene
10ug
343 EUR
M-CSF
E21-417
EnoGene
10ug
343 EUR
GM-CSF
E21-J46
EnoGene
10ug
343 EUR
CSF Tubes
213361-(V100)
ImmunoStep
100 tubes
1688 EUR
CSF Tubes
213361-(V25)
ImmunoStep
25 tubes
505 EUR
CSF Tubes
213361-(V6)
ImmunoStep
6 tubes
186.5 EUR
CSF Tubes
abx290032-100tubes
Abbexa
100 tubes
1957 EUR
CSF Tubes
abx290032-25tubes
Abbexa
25 tubes
662 EUR
CSF Tubes
abx290032-6tubes
Abbexa
6 tubes
314 EUR
Recombinant Mouse M-CSF/CSF-1 Protein
RP01216
Abclonal
10 μg
202 EUR
Recombinant human M-CSF/CSF-1 Protein
RP01221
Abclonal
10 μg
230 EUR
G-CSF/ Rat G- CSF ELISA Kit
ELA-E0042r
Lifescience Market
96 Tests
886 EUR
G-CSF, Human
HY-P7015
MedChemExpress
100ug
946 EUR
GM-CSF, Human
HY-P7016A
MedChemExpress
50ug
441 EUR
M-CSF, Human
HY-P7050
MedChemExpress
50ug
612 EUR
M-CSF, Mouse
HY-P7085
MedChemExpress
10ug
268 EUR
G-CSF, Rat
HY-P7093
MedChemExpress
100ug
1187 EUR
GM-CSF, Mouse
HY-P7361
MedChemExpress
50ug
497 EUR
M-CSF, Rat
HY-P7386
MedChemExpress
10ug
268 EUR
M-CSF/CSF1
E21-B34
EnoGene
10ug
343 EUR
GM-CSF/CSF2
E21-C79
EnoGene
10ug
343 EUR
His-GM-CSF
E13-010-1
EnoGene
10μg
291 EUR
His-GM-CSF
E13-010-2
EnoGene
50μg
700 EUR
His-G-CSF
E13-011-1
EnoGene
10μg
291 EUR
His-G-CSF
E13-011-2
EnoGene
50μg
700 EUR
G - CSF Human
PR27066
Neuromics
2 ug
344 EUR
G - CSF Mouse
PR27067
Neuromics
2 ug
191 EUR
GM - CSF Human
PR27068
Neuromics
2 ug
191 EUR
GM - CSF Rat
PR27071
Neuromics
2 ug
148 EUR
GM - CSF Sf9
PR27072
Neuromics
2 ug
148 EUR
GM - CSF Mouse
PR27074
Neuromics
2 ug
191 EUR
M-CSF Human
PR27079
Neuromics
2 ug
148 EUR
rHu G-CSF
AK8270-0002
Akron Biotech
2µg
Ask for price
rHu G-CSF
AK8270-0010
Akron Biotech
10µg
Ask for price
rHu G-CSF
AK8270-0100
Akron Biotech
100µg
Ask for price
rHu G-CSF
AK8270-1000
Akron Biotech
1mg
Ask for price
rHu GM-CSF
AK9707-0005
Akron Biotech
5µg
Ask for price
rHu GM-CSF
AK9707-0020
Akron Biotech
20µg
Ask for price
rHu GM-CSF
AK9707-0100
Akron Biotech
100µg
Ask for price
rHu GM-CSF
AK9707-1000
Akron Biotech
1mg
Ask for price
G-CSF, Human
LF-P0270
Abfrontier
10 ug
270 EUR
G-CSF, Human
LF-P0270A
Abfrontier
100 ug
1811 EUR
GM-CSF, Human
LF-P0278
Abfrontier
10 ug
270 EUR
GM-CSF, Human
LF-P0278A
Abfrontier
100 ug
1811 EUR
anti-G-CSF
LF-PA0229
Abfrontier
100 ul
334 EUR
anti-GM-CSF
YF-PA11125
Abfrontier
100 ug
403 EUR
anti-G-CSF
YF-PA11129
Abfrontier
50 ul
363 EUR
anti-G-CSF
YF-PA11130
Abfrontier
50 ug
363 EUR
anti-G-CSF
YF-PA11131
Abfrontier
100 ul
403 EUR
anti-G-CSF
YF-PA11132
Abfrontier
100 ug
403 EUR
G-CSF Antibody
5094-100
Biovision
316 EUR
G-CSF Antibody
5094-30T
Biovision
146 EUR
G-CSF Antibody
5094R-100
Biovision
338 EUR
G-CSF Antibody
5094R-30T
Biovision
146 EUR
GM-CSF Antibody
5100-100
Biovision
316 EUR
GM-CSF Antibody
5100-30T
Biovision
146 EUR
GM-CSF Antibody
5101-100
Biovision
316 EUR
GM-CSF Antibody
5101-30T
Biovision
146 EUR
M-CSF Antibody
5237-100
Biovision
316 EUR
M-CSF Antibody
5237-30T
Biovision
146 EUR
M-CSF Antibody
5238-100
Biovision
316 EUR
M-CSF Antibody
5238-30T
Biovision
146 EUR
GM-CSF antibody
70-GR30
Fitzgerald
50 ug
298 EUR
GM-CSF protein
30R-AG014
Fitzgerald
5 ug
133 EUR
GM-CSF protein
30R-AG016
Fitzgerald
50 ug
529 EUR
GM-CSF protein
30R-AG022
Fitzgerald
20 ug
273 EUR
M-CSF protein
30R-AM004
Fitzgerald
50 ug
691 EUR
M-CSF protein
30R-AM005
Fitzgerald
10 ug
273 EUR
M-CSF protein
30R-AM069
Fitzgerald
10 ug
273 EUR
M-CSF antibody
70R-CR018
Fitzgerald
100 ug
381 EUR
GM-CSF antibody
70R-GR026
Fitzgerald
50 ug
273 EUR
M-CSF antibody
70R-MG004
Fitzgerald
50 ug
273 EUR
G-CSF-R/ Rat G- CSF- R ELISA Kit
ELA-E2217r
Lifescience Market
96 Tests
886 EUR
G-CSF ab/ Rat G- CSF ab ELISA Kit
ELA-E1717r
Lifescience Market
96 Tests
886 EUR
Recombinant Human M-CSF/ CSF-1 Protein, Untagged, E.coli-100ug
QP10351-ec-100ug
EnQuireBio
100ug
1396 EUR
Recombinant Human M-CSF/ CSF-1 Protein, Untagged, E.coli-10ug
QP10351-ec-10ug
EnQuireBio
10ug
290 EUR
Recombinant Human M-CSF/ CSF-1 Protein, Untagged, E.coli-250ug
QP10351-ec-250ug
EnQuireBio
250ug
2457 EUR
Recombinant Human M-CSF/ CSF-1 Protein, Untagged, E.coli-2ug
QP10351-ec-2ug
EnQuireBio
2ug
154 EUR
Recombinant Mouse M-CSF/ CSF-1 Protein, Untagged, E.coli-100ug
QP10469-ec-100ug
EnQuireBio
100ug
1396 EUR
Recombinant Mouse M-CSF/ CSF-1 Protein, Untagged, E.coli-10ug
QP10469-ec-10ug
EnQuireBio
10ug
290 EUR
Recombinant Mouse M-CSF/ CSF-1 Protein, Untagged, E.coli-250ug
QP10469-ec-250ug
EnQuireBio
250ug
2457 EUR
Recombinant Mouse M-CSF/ CSF-1 Protein, Untagged, E.coli-2ug
QP10469-ec-2ug
EnQuireBio
2ug
154 EUR
Recombinant Human M-CSF/ CSF-1 Protein, Untagged, E.coli-1mg
QP5223-1mg
EnQuireBio
1mg
4054 EUR
Recombinant Human M-CSF/ CSF-1 Protein, Untagged, E.coli-500ug
QP5223-500ug
EnQuireBio
500ug
2503 EUR
Recombinant Mouse M-CSF/ CSF-1 Protein, Untagged, E.coli-1mg
QP5408-1mg
EnQuireBio
1mg
4054 EUR
Recombinant Mouse M-CSF/ CSF-1 Protein, Untagged, E.coli-500ug
QP5408-500ug
EnQuireBio
500ug
2503 EUR
Recombinant Rat M-CSF/ CSF-1 Protein, Untagged, E.coli-100ug
QP5518-100ug
EnQuireBio
100ug
708 EUR
Recombinant Rat M-CSF/ CSF-1 Protein, Untagged, E.coli-10ug
QP5518-10ug
EnQuireBio
10ug
237 EUR
Recombinant Rat M-CSF/ CSF-1 Protein, Untagged, E.coli-1mg
QP5518-1mg
EnQuireBio
1mg
4952 EUR
Recombinant Rat M-CSF/ CSF-1 Protein, Untagged, E.coli-1ug
QP5518-1ug
EnQuireBio
1ug
136 EUR
Recombinant Rat M-CSF/ CSF-1 Protein, Untagged, E.coli-500ug
QP5518-500ug
EnQuireBio
500ug
3038 EUR
Recombinant Rat M-CSF/ CSF-1 Protein, Untagged, E.coli-2ug
QP5519-2ug
EnQuireBio
2ug
146 EUR
Recombinant Mouse M-CSF/ CSF-1 Protein, His, E.coli-100ug
QP8587-ec-100ug
EnQuireBio
100ug
571 EUR
Ten milliliters of 500 mmol/LBHT were added to 1 ml of tissue homogenate to prevent sample oxidation. The homogenate was centrifuged at 3000 rpm at 4°C for 10 min. Then 0.2 ml of sample (plasma or tissue homogenate supernatant) and 0.65 ml of diluted MPI reagent were added to a polypropylene microcentrifuge tube. The mixture was vortexed and then 0.15 mL of 12 M HCl was added. The tubes were incubated at 45°C for 60 min and centrifuged at 6000 rpm for 15 min . Then 0.8 ml of the supernatant was measured at 586 nm. MDA standards for the standard curve were obtained by diluting the 10th mm TMOP stock solution. The final concentrations were 2.08, 4.16, 8.33, 12.5 and 16.66 µ mol/L and the test procedure was followed as for the samples. The absorbance was 0.059, 0.124, 0.264, 0.4, and 0.545, respectively [ 10 ].
Leave a Comment